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The risk of cardiovascular (CV) events and mortality is significantly higher in patients with 
systemic rheumatic diseases than in the general population. Although CV involvement 
in such patients is highly heterogeneous and may affect various structures of the heart, 
it can now be diagnosed earlier and promptly treated. Various types of assessments 
are employed for the evaluation of CV risk such as transthoracic or transesophageal 
echocardiography, magnetic resonance imaging (MRI), and computed tomography 
(CT) to investigate valve abnormalities, pericardial disease, and ventricular wall motion 
defects. The diameter of coronary arteries can be assessed using invasive quantitative 
coronarography or intravascular ultrasound, and coronary flow reserve can be assessed 
using non-invasive transesophageal or transthoracic ultrasonography (US), MRI, CT, or 
positron emission tomography (PET) after endothelium-dependent vasodilation. Finally, 
peripheral circulation can be measured invasively using strain-gauge plethysmography 
in an arm after the arterial infusion of an endothelium-dependent vasodilator or non- 
invasively by means of US or MRI measurements of flow-mediated vasodilation of the 
brachial artery. All of the above are reliable methods of investigating CV involvement, but 
more recently, introduced use of speckle tracking echocardiography and 3-dimensional 
US are diagnostically more accurate.
Keywords: systemic rheumatic diseases, coronary artery diseases, plasma asymmetric dimethylarginine, 
computed tomography, atherosclerosis, endothelial dysfunction
iNTRODUCTiON
The risk of cardiovascular (CV) disease due to advanced atherosclerosis is higher in patients with 
systemic rheumatic diseases (SRDs) even in the absence of traditional CV risk factors (1), occurs 
earlier than in the general population, and is frequently asymptomatic in its early stages (2). The 
greater risk can be attributed to factors specifically related to autoimmune diseases such as chronic 
inflammation, disease duration and activity, and glucocorticoid, methotrexate, or antitumor 
necrosis factor-alpha (anti-TNFα) immunosuppression (3). The heart can be affected by various 
pathogenetic mechanisms involving the valves, coronary arteries, the conduction system, and the 
myocardium, endocardium, and pericardium, and their clinical manifestations include pericar-
ditis, myocarditis and myocardial fibrosis, rhythm and conduction disturbances, coronaritis with 
ischemic heart disease, valve diseases, pulmonary hypertension, syncope, and diastolic or systolic 
heart failure (4).
Table 2 | Imaging techniques and their correlations with pathological alterations 
in systemic rheumatic disease patients.
imaging 
technique
inflammation ischemia Scarring vasculitis Coronary 
arteries
Echo No Yes ± no Yes ± no Yes ± no No
Nuclear No Yes ± no Yes ± no Yes ± no No
Computed 
tomography
No No Yes ± no No Yes
CMRI Yes Yes Yes Yes Yes ± no
Table 1 | Imaging techniques for assessing cardiovascular involvement in 
patients with systemic rheumatic diseases.
Measurements
1. Coronary arteries
Invasive: coronary diameter can be assessed using quantitative 
coronarography or intravascular ultrasound
Non-invasive: coronary flow reserve can be assessed using transthoracic  
or transesophageal ultrasonography (US), magnetic resonance 
imaging (MRI), computed tomography, and positron emission 
tomography (PET) after endothelium-dependent vasodilatory 
provocation
2. Peripheral circulation
Invasive: strain-gauge plethysmography of an arm after intra-arterially 
infusing an endothelium-dependent vasodilator
Non-invasive: flow-mediated vasodilation of the brachial artery measured by 
means of US or MRI
evaluation of general atherosclerotic alterations
1. Arterial stiffness parameters:
Pulse wave analysis: augmentation index
Pulse wave velocity
2. Common carotid intima-media thickness (ccIMT) and carotid plaque analysis
3. Determination of coronary calcium content
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Chronic inflammation is a major cause of atherosclerotic 
plaque (5) and endothelial dysfunction, which may be initially 
due to reduced nitric oxide (NO) bioavailability (6).
Non-invasive tests are the preferred means of investigating 
suspected or confirmed coronary artery disease (CAD), valve 
anomalies, and the other morphological and structural changes 
induced by SRDs (7, 8) (Table 1), but this review will also describe 
invasive methods of diagnosing CV involvement in SRD patients 
(Table 2).
SOURCeS aND SeleCTiON CRiTeRia
English-language articles published between January 1995 and 
July 2017 were found in the PubMed, Medline, and Cochrane 
Library databases using the key words “cardiovascular diseases” 
or “atherosclerosis,” “endothelial dysfunction,” “connective tissue 
disease,” “rheumatologic(al) disease” (including “rheumatoid 
arthritis,” “spondyloarthritis,” “systemic lupus erythematosus,” 
“Sjögren’s syndrome,” “mixed connective tissue disease,” “vasculi-
tis”), “cardiovascular tools,” “non-invasive methods” or “invasive 
methods, “echocardiography,” and “coronary flow reserve.” The 
articles and book chapters in the papers’ reference lists were also 
reviewed.
MeTHODS OF evalUaTiNG valve 
abNORMaliTieS, PeRiCaRDial 
DiSeaSeS, aND veNTRiCUlaR wall 
MOTiON DeFeCTS
Transthoracic echocardiography
Transthoracic echocardiography is a non-radiating, widely 
available, inexpensive, reliable, and easily reproducible means of 
precisely and non-invasively assessing pericardial diseases, valve 
anomalies, and defective ventricular wall motion, and Doppler 
analysis can be used to investigate valve function, pulmonary 
pressure, and diastolic left ventricular filling. Although it is opera-
tor dependent, limited in patients with a poor acoustic window, 
and does not allow the tissue characterization needed to detect 
inflammation, it is particularly valuable in diagnosing patients at 
high risk of developing CV disease such as those with rheumatoid 
arthritis (RA).
It was used by Rexhepaj et al. (9) to show that RA patients 
had significantly different early diastolic flow velocity (E), atrial 
flow velocity (A), and E/A ratios from those of control subjects, 
a finding indicating that, even when the size and thickness of 
their left ventricle and their myocardial performance are still 
normal, RA patients may have subclinically impaired left and 
right ventricular (LV and RV) function. Some authors (but not 
others) have found correlations between impaired diastolic 
function and disease duration and extra-articular manifesta-
tions, thus strengthening the hypothesis that chronic systemic 
inflammation is related to cardiac remodeling (10). This view is 
also supported by the fact that treatment with antitumor necrosis 
factor (TNF) agents improves diastolic function and normalizes 
left ventricle morphology within 6–12 months (11, 12).
Transthoracic echocardiography studies have shown that valve 
involvement is particularly frequent in patients with primary 
antiphospholipid syndrome (APS). There is a 32–38% prevalence 
of valve lesions, which mainly affect left-sided valves, valvular 
rings, the cordae tendineae, and other parts of the ventricular 
or atrial endocardium, and are characterized by diffuse leaflet 
thickening, valve stenosis, and often valvular regurgitation (13).
Doppler-derived mitral and pulmonary venous flow velocities 
used to be the only means of measuring diastolic LV filling, but 
the most widely used parameter for assessing diastolic function 
is now E/E’, which combines the findings of trans-mitral pulsed 
wave (PW) Doppler analysis with those of tissue Doppler imaging 
(TDI) (Figure 1).
Transesophageal echocardiography (Tee)
Transesophageal echocardiography is widely acknowledged 
to be more sensitive than TTE in detecting valve lesions and 
intracardiac masses (14), and Turiel et  al. (15) used it to find 
that the prevalence of valve thickening, vegetation, and other 
sources of embolism was 61% in 56 patients with primary APS 
who were followed up for 5 years. Three-dimensional (3D) TEE 
has recently improved the diagnostic sensitivity of traditional 
2D imaging by making it possible to view cross-sections of the 
mitral, aortic, and tricuspid valves (16). It also allows more 
reproducible and accurate measurements of LV volume, mass, 
FiGURe 1 | Example of coronary flow Doppler signal during dypiridamole-induced hyperemia. S, systolic flow; D, diastolic flow.
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and ejection fraction (LVEF), identifies wall motion abnor-
malities more precisely, and makes it possible to study the right 
ventricle, thus improving our understanding of valvular and 
sub-valvular abnormalities (17).
Turiel et al. (15) found valve thickening and/or regurgitation, 
vegetations or masses, and potential embolic sources in 33 out of 
40 APS patients (82%), with the most frequent abnormality (63%) 
being mitral valve thickening. The number of associated and/or 
recurrent thromboembolic events was highest in the patients 
with anticardiolipin antibody titres of >40 GPL units, who also 
showed more TEE-revealed potential embolic sources than the 
patients with titres of <40 GPL units (p < 0.01). TEE can, there-
fore, be recommended in APS patients with clinical findings or 
high anticardiolipin antibody titres in order to characterize their 
cardiac abnormalities and detect possible sources of embolism 
(18), as well as to select the most appropriate treatment.
A recent TEE study found echo-generating mitral or aortic 
valve nodules, aortic atheromas, and mitral or aortic regurgita-
tion in 30 unselected RA patients (19).
Tissue Doppler imaging
Tissue Doppler imaging, which has often been considered a 
reliable means of assessing myocardial deformations, can also 
be used to measure myocardial velocities, although its angle 
dependency means that they can only be used to detect deformi-
ties along the ultrasound beam, whereas the myocardium is 
simultaneously deformed in three dimensions (20).
The low doppler shift frequencies of the energy created by ven-
tricular wall motion, which are filtered out in standard Doppler 
blood flow studies, can be recorded by means of pulsed Doppler 
imaging, whose temporal resolution makes it possible to analyze 
the temporal relationships between waves of systolic and diastolic 
myocardium velocity. Two-dimensional color doppler imaging 
has poor temporal resolution but good spatial resolution, which 
allows the differentiation of sub-endocardial and sub-epicardial 
velocity profiles, whereas the high temporospatial resolution of 
M-mode color-coded Doppler imaging only samples a single 
line. However, both require specific modifications to current 
ultrasound machines.
Tissue Doppler imaging is useful for studying CV involvement 
in patients with SRDs. Birdane et al. (21) found that, depending 
on their age and use of steroids, the diastolic biventricular func-
tion of RA patients is significantly impaired in comparison with 
healthy controls, and D’Alto et  al. (22) found that SSc patients 
have both systolic and diastolic biventricular dysfunction, and 
that their systolic pulmonary artery systolic pressure (sPAP) is 
increased and further deteriorates after 3  years. Furthermore, 
Kama et  al. (23) showed that patients with SSc have abnormal 
diastolic RV and LV function, and abnormal systolic RV func-
tion, with RV wall thickness being found to be the best individual 
predictor of global myocardial performance.
Speckle Tracking echocardiography (STe)
Speckle tracking echocardiography was introduced as a means of 
overcoming the limitations of TDI and allowing the evaluation 
of longitudinal, circumferential, and radial myocardial strain (9). 
It makes it possible to investigate regional myocardial deforma-
tion using the dimensionless parameter of strain (ε): i.e., the 
percentage change from the original size (24, 25). Furthermore, 
as myocardial motion is reflected by displacement, myocardial 
segments change position (displacement) but not their shape 
(deformation) if all of their parts have the same motion over 
FiGURe 2 | STE: systolic myocardial deformation after electromechanical activation. LV: longitudinal strain from the apical four-chamber view: time–strain curves 
show a negative end-systolic strain representing myocardial shortening during systole.
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a given period of time, but become deformed if different parts 
move differently. The use of both ε and displacement makes it 
possible to distinguish the passive movement and active con-
traction of each myocardial segment (26). As first described by 
Heimdal et al. (27), tissue deformation occurs during the cardiac 
cycle, and its rate (i.e., the strain rate, SR) is equivalent to the 
velocity gradient. Both TDI and STE can determine myocardial ε, 
but only angle-independent STE can accurately assess segmental 
myocardial deformation, which it does by means of gray scale-
based, frame-by-frame image analysis. Furthermore, as myocar-
dial ε can be tracked in two dimensions along the wall and not 
only along the ultrasound beam (22), it can be analyzed three 
dimensionally. When it is activated electro-mechanically, systolic 
myocardial deformation is reflected by radial thickening and 
longitudinal and circumferential shortening, thus making STE 
reliable in detecting slight cardiac involvement early in patients 
with connective tissue diseases (Figure 2) (24).
We have used STE strain analysis to find subclinical LV and RV 
abnormalities in RA patients (28). Yiu et al. (29) have shown that 
STE-revealed LV dysfunction is related to rhythm disturbances 
and the poorer functional capacity of patients with SSc, and 
Spethmann et al. (30) found that the systolic LV impairment of 
SSc patients with a preserved LVEF. is primarily due to alterations 
in the basal LV segments Finally, Atzeni et al. (31) have shown 
that STE-measured LV myocardial longitudinal ε is impaired in 
patients with primary Sjögren’s syndrome (pSS) in the absence 
of any clinical evidence of CV disease, and when traditional 
echocardiographic parameters were still negative, which suggests 
a myocardial alteration.
Myocardial Contrast echocardiography 
(MCe)
Myocardial contrast echocardiography is a new portable tech-
nique that uses microbubble contrast agents to visualize the coro-
nary microvasculature and is ideal for non-invasively evaluating 
acute coronary syndromes (ACS) as it simultaneously assesses 
of regional wall motion and myocardial perfusion (32). Recent 
improvements in ultrasonography (US) technology and contrast 
FiGURe 3 | CRMI: a patient with previous anterior myocardial infarction. Late 
enhancement imaging showed transmural infarction in the left anterior 
descending artery.
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agents means that MCE can now be used to assess chest pain, 
diagnose acute myocardial infarction, and establish its prognosis, 
assess successful reperfusion, and distinguish myocardial stun-
ning and myocardial necrosis (32). Possible future applications 
include the detection of inflammation and ultrasound-induced 
thrombolysis in patients with ACS, but further studies are 
required in patients with SRDs.
Cardiac MRi (CMRi)
Cardiac MRI non-invasively, accurately, and reproducibly 
assesses myocardial anatomy and function, and is now gold 
standard means of measuring LVEF, and LV and RV volumes 
(Figure 3) (8, 33–35). The images are constructed on the basis 
of signals produced by the many protons (hydrogen nuclei) that 
are mainly present in the body in the form of water molecules. 
The relaxation of the net proton vector can be attributed to two 
distinct processes that take place at the same time and can pro-
vide important information about human tissues: longitudinal 
(T1) and the transverse (T2) relaxation times. The basic pulse 
sequences used in CMRI are gradient-echo (GE) sequences that 
can form a cine loop and allow the assessment of wall motion and 
function; T1-weighted spin-echo sequences that are useful for 
anatomical imaging; T2-weighted spin-echo sequences that offer 
information about tissue edema. Late gadolinium-enhanced 
(LGE) images taken 15  min after the administration of the 
contrast agent allow the detection of myocardial fibrotic tissue 
(scarring), which appears as a bright area on a background of 
black myocardium (8, 34); non-invasive vessel angiography is 
also possible using a bolus injection of gadolinium.
Cardiac MRI can detect myocardial lesions in patients with 
mixed connective tissue disease (CTD) or cardiac symptoms such 
as myocardial infarction, inflammation, diffuse sub-endocardial 
fibrosis, and defective perfusion (34). It can also diagnose con-
genital heart disease and interstitial fibrosis in patients with 
dilated and infiltrative cardiomyopathies, assess the viability of 
the myocardium in patients with ischemic heart disease, reveal 
ventricular thrombi and constrictive pericarditis, measure valve 
dysfunction and iron overload in T2-weighted images, and assist 
in the evaluation of arrhythmogenic RV dysplasia cardiomyopa-
thy (ARVD/C).
It is the gold standard means of evaluating myocardial viabil-
ity. It has been clearly shown that LV dysfunction in patients with 
CAD may be related to myocardial stunning or hibernation, and 
can, therefore, be reversed (34). CMRI was used to compare 
myocardial structure and function in men and women with RA 
enrolled in the Evaluation of Subclinical Cardiovascular Disease 
and Predictors of Events in Rheumatoid Arthritis study and 
non-RA control subjects enrolled in the Baltimore Multi-Ethnic 
Study of Atherosclerosis, and showed that mean LV mass was 
26 g (18%) less in the RA patients (p < 0.001) (36). There was 
no between-group difference in mean LV end-systolic and end-
diastolic volumes, but mean LVEF, cardiac output, and stroke 
volume were also slightly lower in the RA group. These findings 
support the view that the progression to heart failure in RA 
patients may be due to reduced myocardial mass rather than 
hypertrophy.
LGE CMRI differentiates viable and non-viable myocardium 
and can identify which segments may need to be revascularised. 
It has also recently been shown that CMRI can identify vascu-
litis, myocarditis, and myocardial infarction in patients with 
symptomatic CTD and normal echocardiography findings (34).
CMRI-detected myocardial abnormalities are often encoun-
tered in RA patients with no known cardiac disease and, as they 
are associated with greater RA disease activity, inflammation may 
play a role in their pathogenesis (35). Furthermore, a T2-weighted 
and LGE CMRI study of global and regional morphology and 
systolic function in 94 RA patients with clinically diagnosed 
myocarditis showed greatly increased end-diastolic volumes, 
a reduced EF, thickened antero- and infero-lateral walls associ-
ated with reduced radial and longitudinal thickening, and a con-
siderably higher T2 edema ratio and global LGE scores (37), thus 
suggesting that sustained inflammation gives rise to myocardial 
plasticity and deformation.
MeTHODS OF evalUaTiNG CORONaRY 
aRTeRieS
Stress echocardiography
A pharmacological stress test is indicated for patients who 
cannot exercise adequately because of rheumatological, ortho-
pedic, vascular, or pulmonary conditions. The various ways of 
evaluating coronary flow reserve (CFR) in such patients include 
transthoracic stress echocardiography with dipyridamole, which 
is cheap, simple, and non-invasive (Figure  1) (21, 38). CFR, 
which is assessed in the distal left anterior descending coronary 
artery, is the ratio between peak diastolic velocity during stress 
and at baseline. It is a highly sensitive (>90%) diagnostic marker 
FiGURe 4 | Cardiac CT: patient with high-grade left anterior descending 
artery stenosis (arrow).
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of CAD (39) and highly specific when associated with regional 
wall motion analysis (40). A CFR of <2 indicates the presence 
of coronary stenosis (39), an abnormal reserve in the absence of 
a epicardial coronary stenosis, may indicate an impaired coro-
nary microcirculation in patients with a reperfused myocardial 
infarction, hypertrophic cardiomyopathy, arterial hypertension 
with or without LV hypertrophy, diabetes mellitus, hypercholes-
terolemia, syndrome X, or other diseases (38). A reduced CFR 
correlates with a negative prognosis, and the range of CFR values 
is an independent prognostic indicator in patients with known or 
suspected CAD (41).
Hirata et  al. (42) found that CFR was significantly lower in 
pre-menopausal women with systemic lupus erthymetosus (SLE) 
than in age- and gender-matched controls, and suggested that the 
microvascular impairment may be due to a functional endothelial 
alteration decreasing vasodilation as a result of pharmacological 
stress. Turiel et al. (43) found significantly lower CFR values in 
25 untreated patients with early RA (ERA, a disease duration of 
<1 year) which, in the absence of wall motion abnormalities at 
rest and during pharmacological stress indicated the involve-
ment of the coronary microcirculation and an association with 
endothelial dysfunction. CFR cannot distinguish micro- and 
macro-vascular CAD, but has additional diagnostic value over 
conventional wall motion analysis.
Ciftci et al. (44) have shown that RA patients have increased 
intima-media thickness (IMT) and reduced CFR. Chung et  al. 
(45) found that the prevalence of more severe coronary calcifica-
tion was higher patients with long-standing RA than in those with 
ERA, and Del Rincon et al. (46) demonstrated that ATS is more 
likely than in healthy controls. Accurate coronary microcircula-
tion screening is therefore crucial in the earliest stages of RA, even 
if there are no signs or symptoms of CV involvement.
Endothelial dysfunction and increased carotid artery IMT 
are more prevalent in patients with psoriatic arthritis (PsA) but 
without any conventional CV risk factors or clinically evident 
CV disease than in controls (47). Our comparison of sub-clinical 
cardiac involvement in 22 outpatients meeting the Classification 
of Psoriatic Arthritis (CASPAR) Study Group criteria for PsA 
but no history of CV disease and 35 controls showed that the 
patients had higher asymmetric dimethylarginine levels and a 
significantly reduced CFR (48), and the significant correlation 
between these factors may indicate endothelial dysfunction and 
an impaired coronary microcirculation, thus confirming the view 
of Wakkee and de Jong (47) that active PsA is a risk factor for CV 
disease.
A Danish population cohort study by Ahlehoff et  al. (49), 
which included 34,371 subjects with mild psoriasis, 2,621 with 
severe disease, and 607 with PsA. CV events were more frequent 
in the psoriasis patients, and their frequency increased with 
disease severity, and decreased with age at the time of disease 
onset. The risk was similar in the subjects with severe psoriasis 
alone and those with PsA. Given the high CV burden mainly 
related to endothelial dysfunction and ATS, an early diagnosis is 
fundamental in patients with PsA (47).
Our dypiridamole echocardiography study of 20 patients 
meeting the American College of Rheumatology (ACR) crite-
ria for SSc but with no sign or history of CAD and 20 healthy 
volunteers showed that the former had a significantly lower CFR, 
which seems to support the idea that subjects with diffuse SSc have 
subclinical CV involvement (50). The findings were confirmed by 
Vacca et al. (51) who found that 19 out of 41 patients with SSc 
and no symptoms of CAD who underwent Doppler TTE with an 
adenosine infusion and dobutamine stress echocardiography had 
a reduced CFR, and 16 had wall motion anomalies.
All of the above findings underline the importance of detect-
ing subclinical coronary microcirculation abnormalities, and 
CFR can be a useful marker in SRD patients. It seems that echo-
cardiographic variables such as CFR can be reliable, sensitive, 
and specific means of detecting preclinical cardiac involvement 
relatively inexpensively.
Computed Tomography (CT)
Computed tomography has become a potent means of diagnosis 
that is almost indispensable in clinical practice (Figure 4). It is 
widely available, easy to use, non-invasive, and highly sensitive 
in detecting CAD and evaluating pericardial disease, pericardial 
fluid, and pericardial neoplasms. Given the small diameter 
lumens of coronary arteries, high resolution is critical, but the 
spatial and temporal resolution and volume coverage of modern 
multi-detector row CT systems are sufficient to allow robust 
imaging in many patients (Figure 4) (52).
When CT is used for the purpose of imaging coronary arter-
ies, it is necessary to avoid unnecessarily high radiation doses 
(53). This issue has been addressed by recent advances in scan-
ner technology and image sequencing, as well as randomized 
and controlled trials whose findings indicate that coronary CT 
angiography (CTA) has now become established as a means of 
assessing CAD (54). It can be carried out after the intravenous 
FiGURe 5 | Coronary CT: chronic total occlusion of left anterior descending 
artery.
FiGURe 6 | Coronary TC: chronic total occlusion of left anterior descending 
artery.
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injection of an iodinated contrast agent (coronary CTA), or 
by simply using the contrast-free Agatston or coronary artery 
calcium (CAC) score (55), which correlates closely with total 
coronary calcium levels in histological samples, and measures 
early atherosclerosis. This score is recommended by the American 
College of Cardiology (56) in subjects with unclear results based 
on traditional algorithms of clinical CVD risk, and similarly by 
the European Society of Cardiology (ESC) (57).
After the intravenous injection of a contrast agent, ≥64-
slice CT can visualize the coronary artery lumen providing 
that the patients are carefully selected and prepared. Coronary 
CTA should only be considered for non-obese patients with a 
favorable calcium score who are in sinus rhythm, have a heart 
rate of ≤65  bpm (preferably ≤60  bpm), and can hold their 
breath sufficiently (58): short-acting β-blockers or other heart 
rate-lowering medications are recommended when necessary. 
However, as the specificity of coronary CTA decreases as coro-
nary calcium increases (59), and given the high prevalence of 
coronary artery stenosis in symptomatic subjects with a score of 
>400 (60), coronary CTA is not recommended in patients with 
these characteristics (Figures 5 and 6) (61).
The diagnostic performance of coronary CTA is best in subjects 
with a low-intermediate pretest probability of having the disease, 
and it may, therefore, be useful to rule out coronary stenoses (62). 
It could also be used to assess CV risk in patients with RA as the 
current radiation exposure associated with CTA is ≤3–4 mSv, and 
the typical radiation dose associated with CAC scoring is <1 mSv. 
In patients with these characteristics, good quality images can be 
expected with reasonably little radiation exposure, but coronary 
CTA cannot exclude functional CAD.
Furthermore, newer developments such as fractional flow 
reserve (CT-FFR) require further validation.
Pericardial disease is frequently encountered alone or in 
association with other systemic disorders. Recognizing the typi-
cal manifestations of pericardial disease can be relatively easy, as 
these include acute pericarditis and an audible friction rub, and 
a reported retrosternal pain exacerbated by inspiration or being 
in the supine position. However, as pericardial disease can also 
be associated with non-specific symptoms and equivocal physical 
findings, it may be more difficult to diagnose without using CT, 
which is the most accurate means of imaging the calcified tissue 
associated with chronic pericarditis (63).
Positron emission Tomography (PeT)
Positron emission tomography myocardial perfusion imaging, 
which detects the uptake of positron-emitting radiotracers in the 
heart, allows LV volumes to be precisely measured and used to 
determine myocardial perfusion (64, 65) on the basis of the LV as 
a whole or each of its standard segments. Decreased myocardial 
perfusion may indicate obstructive CAD or a reduced coronary 
microcirculation. PET–CT can identify high-risk ruptured 
atherosclerotic plaques in patients with symptomatic coronary 
and carotid artery disease, and PET can be used to predict 
CV mortality in patients with suspected angina or CAD (65). 
However, its use is limited by its cost, the availability of tracers, 
its use of ionizing radiation, and its restricted ability to assess 
cardiac structures.
NON-iNvaSive aSSeSSMeNTS OF 
aRTeRial iNvOlveMeNT
Carotid Ultrasonography
The ultrastructure of elastic arteries such as the carotid arteries 
can be easily investigated as they are close to the skin. A 7 MHz 
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linear array transducer for B-mode US can be used to assess wall 
abnormalities, and the IMT of the far wall of the common carotid 
arteries [common carotid intima-media thickness (ccIMT)] is 
a major indicator of vascular aging (66) as an IMT of >1 mm 
is a reliable marker of generalized rather than localized carotid 
atherosclerosis (67). Increased ccIMT suggests a higher risk of 
myocardial infarction, peripheral arterial disease and stroke, 
but is only moderately sensitive in predicting future CV events 
(68). The measurement site is crucial for standardization and 
reliability but, although ccIMT assessments are considered to be 
quantitative, they do not allow detailed ultrastructural analysis 
of the whole extracranial carotid system (69): future myocardial 
and cerebrovascular events can be better predicted on the basis 
of the presence of plaques in the carotid system or total plaque 
area than on the basis of ccIMT, but their combination is rec-
ommended in asymptomatic adults at intermediate risk of CV 
events (70).
Many cross-sectional studies have found that patients with RA 
or AS have increased ccIMT indicating accelerated atherosclero-
sis, and patients with PsA, SLE, and SSc have been found to have 
subclinical atherosclerosis (71, 72). Furthermore, the findings of 
one small follow-up cohort study support the view that ccIMT 
can predict future CV events in patients with RA in the long 
term (73). Corrales et al. (74) divided 370 consecutive patients 
with established RA and no history of CV disease into groups 
considered to be at low, intermediate, high, or very high CVD 
risk on the basis of a modified risk score. All of them underwent 
carotid US but only 12% of the low-risk patients showed increased 
cIMT and/or carotid plaques indicating a high CV risk; however, 
these features were found in 65% of the patients at intermediate 
risk, and 85% of those at high or very high risk. CV imaging is, 
therefore, useful when evaluating patients at intermediate CV 
risk (74).
The current European League against Rheumatism 
(EULAR) guidelines indicate RA as an important risk factor 
for atherosclerosis, and so ccIMT may be useful for screening 
RA patients (75).
Flow-Mediated or Nitroglycerine-Mediated 
vasodilatation
Various studies have used flow-mediated (endothelium-dependent) 
vasodilatation (FMD) or nitroglycerine-mediated (endothelium-
independent) vasodilatation (NMD) to assess early endothelial 
dysfunction in RA patients (76–78), and high-resolution US 
measurements of brachial artery FMD and NMD have shown both 
impaired and normal FMD in patients with rheumatic diseases 
(62). Reactive hyperemia leads to a significantly lower percent-
age increase from baseline FMD in RA patients than in healthy 
subjects (5.3 vs 8.3%), but there is no difference in the increase 
in NMD after nitroglycerine administration (18.3 vs 17.5%); 
impaired FMD has also been recorded in young RA patients with 
low disease activity scores (79).
The early endothelial dysfunction indicated by FMD% may 
precede the atherosclerosis revealed by ccIMT, and more marked 
dysfunction may accelerate the atherosclerotic process in RA 
patients (8, 33).
arterial Stiffness
Arterial stiffness, a surrogate measure of an increased risk of CV 
disease, reflects generalized vascular aging and atherosclerosis. 
The standard method of assessing overt atherosclerosis is to 
measure ccIMT; the parameters of arterial stiffness and wave 
reflection are pulse wave velocity (PWV), and transcutane-
ous measurememts of the augmentation index (AIx) (8, 33). 
Alternative methods include measuring aortic distensibility and 
the brachial-ankle elasticity index (baEI). One relatively small 
cross-sectional study of 113 RA patients found that patients in 
remission had significantly lower aPWV and AIx values than 
those with active disease (80). Another recent study of 138 RA 
patients has demonstrated that increased aPWV (as well as 
carotid plaque and cIMT) is predictive of CV events over a mean 
follow-up period of 5.4 years, with a hazard ratio of 1.85 per unit 
(m/s) increase in aPWV (81). The predictive value of the baEI in 
assessing CV risk has been widely studied in the general popula-
tion and, although there are no published longitudinal outcome 
studies of RA patients, the findings of a meta-analysis suggest that 
they have a lower baEI (82).
New diagnostic techniques are needed to predict early 
endothelial dysfunction and overt atherosclerosis (33, 83) and 
identify patients at high risk of CV morbidity and mortality 
easily and in a cost-effective manner. It is likely that the new 3D 
carotid and aortic approaches will be a step in this direction.
CONClUSiON
The increased CV mortality and morbidity in patients with 
SRDs is mainly due to atherosclerotic disease. There are vari-
ous invasive and non-invasive means that can reliably screen, 
diagnose, and monitor the follow-up of CV manifestations in 
these patients. There is reasonable evidence to support the use 
of carotid US but, although newer imaging techniques such as 
CMRI and CT may improve risk stratification, there is still a lack 
of concrete data.
ReSeaRCH aGeNDa
Carotid IMT has been specifically validated in cohorts of RA 
patients but only provides a single, non-dynamic measurement; 
it has not yet been shown that serial measurements are helpful in 
assessing ongoing CV risk as the results of small-scale prospective 
studies are conflicting. Although there are extensive prognostic 
outcome data concerning other diseases associated with a high 
risk of CV disease, the prognostic value of the baEI has not 
yet been assessed in longitudinal studies of RA patients. These 
aspects need to be evaluated and developed in these cohort of 
the patients.
The currently available clinical evidence concerning the 
use of imaging techniques in SRD patients supports the use of 
echocardiography but, although the findings of CMR, PET, CT, 
and hybrid imaging studies are promising, there is still a need 
for additional data before their clinical use can be recommended.
New means of individualizing treatment could lead to a 
more realistically achievable form of “personalized medicine” 
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that would allow early and effective diagnostics, reduce 
hospitalization, and decrease morbidity and/or mortality in 
SRD patients. Bearing this in mind, cost effectiveness should 
not only be considered in the short term but also in the 
long term.
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